Jennison Associates LLC Buys 125,946 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Jennison Associates LLC grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWSTFree Report) by 523.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 150,022 shares of the company’s stock after acquiring an additional 125,946 shares during the period. Jennison Associates LLC owned 0.26% of Twist Bioscience worth $5,147,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the 4th quarter valued at $30,000. International Assets Investment Management LLC boosted its position in shares of Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares in the last quarter. Brown Advisory Inc. acquired a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $225,000. Aigen Investment Management LP bought a new position in Twist Bioscience in the fourth quarter valued at approximately $244,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Twist Bioscience by 354.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,674 shares of the company’s stock valued at $246,000 after purchasing an additional 5,204 shares during the last quarter.

Insider Activity

In related news, SVP Paula Green sold 918 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $47,120.94. Following the transaction, the senior vice president now directly owns 90,593 shares of the company’s stock, valued at approximately $4,650,138.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Emily M. Leproust sold 4,163 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Paula Green sold 918 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $47,120.94. Following the sale, the senior vice president now directly owns 90,593 shares in the company, valued at approximately $4,650,138.69. The disclosure for this sale can be found here. Insiders sold a total of 18,728 shares of company stock valued at $785,980 over the last three months. Corporate insiders own 3.92% of the company’s stock.

Analyst Ratings Changes

TWST has been the subject of several research analyst reports. Guggenheim started coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. TD Cowen boosted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Robert W. Baird raised their target price on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Evercore ISI upped their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Scotiabank raised their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Twist Bioscience has an average rating of “Buy” and a consensus target price of $49.75.

View Our Latest Stock Analysis on Twist Bioscience

Twist Bioscience Stock Performance

Shares of TWST stock opened at $50.50 on Wednesday. The company has a market cap of $2.94 billion, a P/E ratio of -15.03 and a beta of 1.80. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $55.26. The stock has a 50 day simple moving average of $46.29 and a two-hundred day simple moving average of $39.02.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same period last year, the business posted ($1.06) EPS. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Further Reading

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWSTFree Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.